These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30830488)

  • 21. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells.
    Sun H; Wang G; Peng Y; Zeng Y; Zhu QN; Li TL; Cai JQ; Zhou HH; Zhu YS
    Oncol Rep; 2015 Jun; 33(6):3045-52. PubMed ID: 25846769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
    Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
    Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of
    Mitobe Y; Iino K; Takayama KI; Ikeda K; Suzuki T; Aogi K; Kawabata H; Suzuki Y; Horie-Inoue K; Inoue S
    Cancer Res; 2020 Jun; 80(11):2230-2242. PubMed ID: 32213542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
    Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
    Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
    Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.
    Guo S; Li Y; Tong Q; Gu F; Zhu T; Fu L; Yang S
    PLoS One; 2012; 7(12):e52380. PubMed ID: 23285017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.
    Bentin Toaldo C; Alexi X; Beelen K; Kok M; Hauptmann M; Jansen M; Berns E; Neefjes J; Linn S; Michalides R; Zwart W
    BMC Cancer; 2015 Aug; 15():588. PubMed ID: 26272591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
    Shao G; Fan X; Zhang P; Liu X; Huang L; Ji S
    Aging (Albany NY); 2021 Feb; 13(4):4962-4975. PubMed ID: 33668040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
    Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
    Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader.
    Zhao Y; Zhao C; Lu J; Wu J; Li C; Hu Z; Tian W; Yang L; Xiang J; Zhou H; Deng Z; Huang J; Hong K
    Pharmacol Res; 2019 Aug; 146():104294. PubMed ID: 31175940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen-Inducible LncRNA
    Horie K; Takagi K; Takeiwa T; Mitobe Y; Kawabata H; Suzuki T; Ikeda K; Inoue S
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.
    Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A
    Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines.
    Qiu J; Wang X; Guo X; Zhao C; Wu X; Zhang Y
    Oncol Rep; 2009 Oct; 22(4):935-41. PubMed ID: 19724876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells.
    Wu H; Wang G; Wang Z; An S; Ye P; Luo S
    FEBS J; 2016 Jun; 283(12):2259-71. PubMed ID: 26433127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.